SLC5A2 and myocardial infarction: The former meta-analysis lacked any data on the safety profile of SGLT2 inhibitors as well as functional and structural heart parameters like NT-pro BNP and LVEF, which are crucial for understanding the impact of SGLT2 inhibitors on cardiac remodeling post-myocardial infarction[33].